Myriad Genetics Inc. (MYGN)

27.30
NASDAQ : Health Technology
Prev Close 27.97
Day Low/High 26.62 / 27.95
52 Wk Low/High 22.04 / 48.77
Avg Volume 1.39M
Exchange NASDAQ
Shares Outstanding 73.87M
Market Cap 2.07B
EPS 0.10
P/E Ratio 463.33
Div & Yield N.A. (N.A)

Latest News

Prolaris® Test Identifies Men With Prostate Cancer Who Can Safely Defer Treatment

Prolaris® Test Identifies Men With Prostate Cancer Who Can Safely Defer Treatment

65 Percent of Patients Remained on Active Surveillance for More than Four Years

Myriad Genetics To Present At The 2019 Morgan Stanley Global Healthcare Conference

Myriad Genetics To Present At The 2019 Morgan Stanley Global Healthcare Conference

SALT LAKE CITY, Aug. 30, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc.

INVESTOR ALERT: Kirby McInerney LLP Announces An Investigation Of Shareholder Claims Against Myriad Genetics, Inc.

INVESTOR ALERT: Kirby McInerney LLP Announces An Investigation Of Shareholder Claims Against Myriad Genetics, Inc.

The law firm of Kirby McInerney LLP is investigating potential claims against Myriad Genetics, Inc.

INVESTIGATION REMINDER: The Schall Law Firm Announces It Is Investigating Claims Against Myriad Genetics, Inc. And Encourages Investors With Losses In Excess Of $100,000 To Contact The Firm

INVESTIGATION REMINDER: The Schall Law Firm Announces It Is Investigating Claims Against Myriad Genetics, Inc. And Encourages Investors With Losses In Excess Of $100,000 To Contact The Firm

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Myriad Genetics, Inc.

Myriad Applauds The U.S. Preventive Services Task Force Recommendation On BRCA-Related Cancer Prevention

Myriad Applauds The U.S. Preventive Services Task Force Recommendation On BRCA-Related Cancer Prevention

More Women May Benefit from Hereditary Cancer Risk Assessment and Genetic Testing

SHAREHOLDER ALERT: Investigation Of Myriad Genetics Announced By Holzer & Holzer, LLC

SHAREHOLDER ALERT: Investigation Of Myriad Genetics Announced By Holzer & Holzer, LLC

Holzer & Holzer, LLC is investigating whether certain statements made by Myriad Genetics, Inc.

EQUITY ALERT: Rosen Law Firm Announces Investigation Of Securities Claims Against Myriad Genetics, Inc. - MYGN

EQUITY ALERT: Rosen Law Firm Announces Investigation Of Securities Claims Against Myriad Genetics, Inc. - MYGN

Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of Myriad Genetics, Inc.

Hagens Berman Investigating Myriad Genetics (MYGN) For Possible Disclosure Violations, Investors With Losses Should Contact Firm

Hagens Berman Investigating Myriad Genetics (MYGN) For Possible Disclosure Violations, Investors With Losses Should Contact Firm

SAN FRANCISCO, Aug. 19, 2019 /PRNewswire/ -- Hagens Berman notifies investors in Myriad Genetics, Inc.

Investor Alert: Kaplan Fox Investigates Myriad Genetics, Inc.

Investor Alert: Kaplan Fox Investigates Myriad Genetics, Inc.

NEW YORK, Aug. 16, 2019 /PRNewswire/ -- Kaplan Fox & Kilsheimer LLP ( www.

Myriad Genetics Sinks on Fourth-Quarter Earnings and Revenue Miss

Myriad Genetics Sinks on Fourth-Quarter Earnings and Revenue Miss

Myriad Genetics tumbles after missing Wall Street's fiscal fourth-quarter earnings and revenue expectations.

Myriad Genetics Reports Fiscal Fourth-Quarter And Full-Year 2019 Financial Results

Myriad Genetics Reports Fiscal Fourth-Quarter And Full-Year 2019 Financial Results

Total Fourth-Quarter Revenues of $215.4 Million Fourth-Quarter Diluted EPS of ($0.

Myriad To Announce Fiscal Fourth-Quarter 2019 Financial Results On August 13, 2019

Myriad To Announce Fiscal Fourth-Quarter 2019 Financial Results On August 13, 2019

SALT LAKE CITY, Aug. 06, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc.

Notable Thursday Option Activity: MYGN, GPRE, SNDX

Notable Thursday Option Activity: MYGN, GPRE, SNDX

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Myriad Genetics, Inc. , where a total volume of 4,388 contracts has been traded thus far today, a contract volume which is representative of approximately 438,800 underlying shares (given that every 1 contract represents 100 underlying shares).

First Week Of MYGN January 2019 Options Trading

First Week Of MYGN January 2019 Options Trading

Investors in Myriad Genetics, Inc. saw new options begin trading this week, for the January 2019 expiration.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: AAME, AYX, CRUS, FG, MUR, OHI, OTIV, SINO, STAA Downgrades: ABB, ANDE, ATVI, BDC, DVA, EGN, GAIA, GCI, LBTYA, LBTYB, LBTYK, MYE, MYGN, OSUR, PAR, SMG, SSB, TISI, VAC Initiations: ANGI, JBGS, PQG, ROKU Read on to get TheStreet Quant Ratings' detailed report:

First Week Of September 21st Options Trading For Myriad Genetics (MYGN)

First Week Of September 21st Options Trading For Myriad Genetics (MYGN)

Investors in Myriad Genetics, Inc. saw new options become available this week, for the September 21st expiration.

MYRIAD GENETICS 24 HOUR DEADLINE ALERT: Approximately 24 Hours Remain; ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Deadline In Class Action Lawsuit Against Myriad Genetics, Inc. - MYGN

MYRIAD GENETICS 24 HOUR DEADLINE ALERT: Approximately 24 Hours Remain; ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Deadline In Class Action Lawsuit Against Myriad Genetics, Inc. - MYGN

ClaimsFiler, a FREE shareholder information service, reminds investors that they have only until June 19, 2018 to file lead plaintiff applications in a securities class action lawsuit against Myriad Genetics, Inc.

The Law Offices Of Howard G. Smith Reminds Investors Of June 19th Deadline In The Class Action Lawsuit Against Myriad Genetics, Inc. (MYGN)

The Law Offices Of Howard G. Smith Reminds Investors Of June 19th Deadline In The Class Action Lawsuit Against Myriad Genetics, Inc. (MYGN)

Law Offices of Howard G. Smith reminds investors of the June 19, 2018 deadline to file a lead plaintiff motion in the class action filed on behalf of investors that purchased Myriad Genetics, Inc.

Deadline Alert: Glancy Prongay & Murray LLP Reminds Investors Of The Deadline In The Class Action Lawsuit Against Myriad Genetics, Inc. Investors (MYGN)

Deadline Alert: Glancy Prongay & Murray LLP Reminds Investors Of The Deadline In The Class Action Lawsuit Against Myriad Genetics, Inc. Investors (MYGN)

National securities law firm Glancy Prongay & Murray LLP ("GPM") reminds investors of the  June 19, 2018 deadline to file a lead plaintiff motion in the class action filed on behalf of investors that purchased Myriad Genetics, Inc.

FINAL DEADLINE NOTICE: Kaskela Law LLC Alerts Myriad Genetics, Inc. Investors Of Class Action Lawsuit And Important June 19, 2018 Deadline

FINAL DEADLINE NOTICE: Kaskela Law LLC Alerts Myriad Genetics, Inc. Investors Of Class Action Lawsuit And Important June 19, 2018 Deadline

Kaskela Law LLC announces that a class action lawsuit has been filed against Myriad Genetics, Inc.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: ADM, AFSI, CKX, EML, EVH, GDEN, MVC, MYGN, PANW, SO, SYKE, TARO Downgrades: IRCP, RMCF, UEIC, WYND Initiations: CALA, FG, MTNB Read on to get TheStreet Quant Ratings' detailed report:

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders With Losses On Their Investment In Myriad Genetics, Inc. Of Class Action Lawsuit And Upcoming Deadline - MYGN

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders With Losses On Their Investment In Myriad Genetics, Inc. Of Class Action Lawsuit And Upcoming Deadline - MYGN

Pomerantz LLP announces that a class action lawsuit has been filed against Myriad Genetics, Inc.

LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 In Myriad Genetics, Inc. To Contact The Firm

LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 In Myriad Genetics, Inc. To Contact The Firm

Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Myriad Genetics, Inc.

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders With Losses On Their Investment In Myriad Genetics, Inc. Of Class Action Lawsuit And Upcoming Deadline - MYGN

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders With Losses On Their Investment In Myriad Genetics, Inc. Of Class Action Lawsuit And Upcoming Deadline - MYGN

Pomerantz LLP announces that a class action lawsuit has been filed against Myriad Genetics, Inc.

MYRIAD GENETICS SHAREHOLDER ALERT: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Myriad Genetics, Inc. - MYGN

MYRIAD GENETICS SHAREHOLDER ALERT: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Myriad Genetics, Inc. - MYGN

ClaimsFiler, a FREE shareholder information service, reminds investors that they have until June 19, 2018 to file lead plaintiff applications in a securities class action lawsuit against Myriad Genetics, Inc.

TheStreet Quant Rating: C (Hold)